Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Original Research

Published on 13 Oct 2023

Factors influencing adherence to non-communicable disease medication in India: secondary analysis of cross-sectional data from WHO - SAGE2

in Drugs Outcomes Research and Policies

Abraham Tolley
Kirpal Grewal
Alessa Weiler
Anna Maria Papameletiou
Refaat Hassan
Saurav Basu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1183818

6,361 views
5 citations

Systematic Review

Published on 13 Oct 2023

Reimbursement decision-making system in Poland systematically compared to other countries

in Drugs Outcomes Research and Policies

Aneta Mela
Elżbieta Rdzanek
Janusz Jaroszyński
Marzena Furtak-Niczyporuk
Mirosław Jabłoński
Maciej Niewada

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1153680

4,266 views
2 citations

Original Research

Published on 13 Oct 2023

New terminology of medication adherence enabling and supporting activities: ENABLE terminology

in Drugs Outcomes Research and Policies

Przemyslaw Kardas
Emma Aarnio
Tamas Agh
Job F. M. van Boven
Alexandra Lelia Dima
Cristina Mihaela Ghiciuc
Fatjona Kamberi
Guenka Ivanova Petrova
Urska Nabergoj Makovec
Indrė Trečiokienė

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1254291

5,017 views
8 citations

Systematic Review

Published on 13 Oct 2023

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies

in Drugs Outcomes Research and Policies

Chun Xing Li
Tian Tian Liu
Qian Zhang
Qing Xie
Xu Hua Geng
Chun Xia Man
Jia Yi Li
Xin Ying Mao
Yue Qiao
Hua Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1275060

5,115 views
12 citations

Opinion

Published on 12 Oct 2023

Seven-year exclusivity and beyond for drugs of rare diseases in China

in Drugs Outcomes Research and Policies

Yale Jiang
Huiyao Huang
Guo Zhao
Peiwen Ma
Liang Zhang
Shuhang Wang
Ning Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1223056

3,174 views
2 citations

Original Research

Published on 11 Oct 2023

Does China improve social welfare after implementing the national volume-based procurement?

in Drugs Outcomes Research and Policies

Huan Wang
Ya-Tong Huo
Qian Zhuang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1178026

3,043 views
4 citations

Original Research

Published on 10 Oct 2023

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study

in Drugs Outcomes Research and Policies

Hao Liu
Yumin Li
Jie Li
Qiongchi Zhang
Jingtao Wu
Xinyu Li
Liesu Meng
Shuai Cao
Haopeng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1199031

6,294 views
15 citations

Policy and Practice Reviews

Published on 09 Oct 2023

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

in Drugs Outcomes Research and Policies

Kurt Miller
Uwe May
Wolf-Dietrich Beecken
Georgios Hatzichristodoulou
Michael Böhm
Stefan Fink

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1254706

14,352 views

Original Research

Published on 09 Oct 2023

New pricing models for generic medicines to ensure long-term sustainable competition in Europe

in Drugs Outcomes Research and Policies

Clement Francois
Gabriela Gawlik
Jorge Mestre-Ferrandiz
Adrian Pana
Julian Perelman
John Yfantopoulos
Steven Simoens

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1200641

7,772 views
6 citations

Original Research

Published on 09 Oct 2023

Effects of public reporting of prescription indicators on patient choices: evidence from propensity scores matching

in Drugs Outcomes Research and Policies

Manli Chen
Xinping Zhang
Chaojie Liu
Haihong Chen
Dan Wang
Chenxi Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1110653

1,438 views

Original Research

Published on 06 Oct 2023

Real-world study of the leakage of two types of infusion bags in multicenter pharmacy intravenous admixture service (PIVAS)

in Drugs Outcomes Research and Policies

Yanchao Yin
Wei Fu
Wenhua Liu
Feie Li
Xuepeng Gong
Dong Liu
Juan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1273020

3,959 views

Original Research

Published on 06 Oct 2023

Exploring the perspectives of pharmaceutical experts and healthcare practitioners on senolytic drugs for vascular aging-related disorder: a qualitative study

in Drugs Outcomes Research and Policies

Li Ping Wong
Haridah Alias
Kit Mun Tan
Pooi Fong Wong
Dharmani Devi Murugan
Zhijian Hu
Yulan Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1254470

3,071 views
4 citations

Original Research

Published on 04 Oct 2023

Key elements in the quality assessment of a type 3 medication review

in Drugs Outcomes Research and Policies

Anneleen Robberechts
Melissa Michielsen
Stephane Steurbaut
Guido R. Y. De Meyer
Hans De Loof

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1258364

3,006 views
5 citations

Original Research

Published on 03 Oct 2023

Revealing the dynamic landscape of drug-drug interactions through network analysis

in Drugs Outcomes Research and Policies

Eugene Jeong
Bradley Malin
Scott D. Nelson
Yu Su
Lang Li
You Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1211491

3,110 views
1 citation

Review

Published on 03 Oct 2023

Statistical considerations in long-term efficacy evaluation of anti-cancer therapies

in Drugs Outcomes Research and Policies

Ruobing Li
Jingyi Zhang
Jingzhao Wang
Jun Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1265953

3,499 views
1 citation

Policy and Practice Reviews

Published on 02 Oct 2023

Evaluating clinical pharmacists’ involvement in postoperative acute pain services: a multicenter survey in Guangdong Province, China

in Drugs Outcomes Research and Policies

Junxiong Lu
Mingzhen Chen
Guansheng He
Binwei Chen
Ruolun Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1283071

1,617 views